Stock Groups

AstraZeneca to invest $360 million in new Irish drug manufacturing site By Reuters

by Mike Robinson

[ad_1]

© Reuters. As part of the COVID-19 vaccination campaign in Belgium, the AstraZeneca logo was spotted outside AstraZeneca’s Brussels office. REUTERS/Johanna Geron

(Reuters) – AstraZeneca (NASDAQ:) said on Tuesday it would invest $360 million to develop an advanced manufacturing facility in Ireland to produce primary ingredients for medicines.

Anglo-Swedish drugmaker has many drugs in development, as well as a wide range of treatments for heart disease and cancer. It purchased Alexion (NASDAQ) in July for $39B.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]